CAP合作制定实体瘤免疫检查点抑制剂治疗中错配修复与微卫星不稳定检测指南
美国病理学家协会联合分子病理学协会和结直肠癌抗争组织制定循证指南,旨在确定实体瘤患者考虑免疫检查点抑制剂治疗时错配修复缺陷的最佳临床实验室检测。通过系统文献综述和GRADE方法,制定了6条推荐和3条良好实践声明。结直肠癌和胃肠道其他癌症的证据多于胃肠道外癌症,最佳检测取决于癌症类型。
要点
- 最佳检测方法取决于癌症类型。
- 胃肠道和子宫内膜癌有较多证据支持特定检测。
- 胃肠道外多数癌症证据不足,免疫组化是可接受方法。
核心结论
- 最佳检测取决于癌症类型。
- 对于胃肠道外和子宫内膜以外的大多数癌症类型,已发表证据不足以推荐特定临床检测。
- 缺乏已发表证据时,免疫组化是大多数临床实验室可用的可接受方法。
研究设计与样本
- 美国病理学家协会召集专家小组进行系统文献综述并制定推荐。
- 采用美国国家医学院认可的GRADE方法,基于可用证据、证据强度、公开评论反馈和专家小组共识得出推荐。
主要发现
- 制定了6条推荐和3条良好实践声明。
- 结直肠癌和胃肠道其他癌症的证据多于胃肠道外癌症。
临床怎么用
- 对于考虑免疫检查点抑制剂治疗的实体瘤患者,应根据癌症类型选择错配修复检测方法。
- 在缺乏证据的癌症类型中,可优先采用免疫组化检测错配修复状态。
局限性
- 对于胃肠道外和子宫内膜以外的大多数癌症类型,已发表证据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: The US Food and Drug Administration (FDA) approved immune checkpoint inhibitor therapy for patients with advanced solid tumors that have DNA mismatch repair defects or high levels of microsatellite instability; however, the FDA provided no guidance on which specific clinical assays should be used to determine mismatch repair status. OBJECTIVE.—: To develop an evidence-based guideline to identify the optimal clinical laboratory test to identify defects in DNA mismatch repair in patients with solid tumor malignancies who are being considered for immune checkpoint inhibitor therapy. DESIGN.—: The College of American Pathologists convened an expert panel to perform a systematic review of the literature and develop recommendations. Using the National Academy of Medicine-endorsed Grading of Recommendations Assessment, Development and Evaluation approach, the recommendations were derived from available evidence, strength of that evidence, open comment feedback, and expert panel consensus. Mismatch repair immunohistochemistry, microsatellite instability derived from both polymerase chain reaction and next-generation sequencing, and tumor mutation burden derived from large panel next-generation sequencing were within scope. RESULTS.—: Six recommendations and 3 good practice statements were developed. More evidence and evidence of higher quality were identified for colorectal cancer and other cancers of the gastrointestinal (GI) tract than for cancers arising outside the GI tract. CONCLUSIONS.—: An optimal assay depends on cancer type. For most cancer types outside of the GI tract and the endometrium, there was insufficient published evidence to recommend a specific clinical assay. Absent published evidence, immunohistochemistry is an acceptable approach readily available in most clinical laboratories.
引用
- Bartley AN, Mills AM, Konnick E, et al. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer. Arch Pathol Lab Med. 2022. PMID: 35920830. doi:10.5858/arpa.2021-0632-CP
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。